{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PCS IX","nct_id":"NCT02685397","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pcs-ix-nct02685397. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PCS IX","arms":[{"description":"Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)","label":"LHRH agonist + Enzalutamide","type":"ACTIVE_COMPARATOR"},{"description":"Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment","label":"LHRH agonist + Enzalutamide + SBRT","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2041-08","type":"ESTIMATED"},"conditions":["Castration-resistant Prostate Cancer Patients with Oligometastases"],"enrollment":{"count":102,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Leuprolide Acetate","otherNames":["Eligard","Lupron"],"type":"DRUG"},{"name":"Goserelin Acetate","otherNames":["ZOLADEX"],"type":"DRUG"},{"name":"Triptorelin","otherNames":["Trelstar"],"type":"DRUG"},{"name":"Enzalutamide","otherNames":["Xtandi"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy","otherNames":["SBRT"],"type":"RADIATION"}],"last_update":"2024-12-04","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","official_title":"The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiographic Progression-free Survival","timeFrame":"5 years"}],"references":[{"citation":"Niazi T, Saad F, Tisseverasinghe S, Koul R, Thibault I, Chung PWM, Wakil G, Lock M, Delouya G, Bahoric B, Feifer A, Agnihotram VR, Tsakiridis T, Cury FL, Dahmane R, Patil NG, Tyldesley S. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Sep;26(9):1158-1167. doi: 10.1016/S1470-2045(25)00351-1.","pmid":"40907514","type":"DERIVED"}],"start_date":{"date":"2016-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","url":"https://clinicaltrials.gov/study/NCT02685397"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pcs-ix-nct02685397"}